Paige.ai: Advancing Cancer Diagnosis with AI-Powered Precision Pathology

Paige.ai is a pioneering company transforming cancer care through cutting-edge artificial intelligence in pathology. Specializing in diagnostic AI for clinical and life sciences, it delivers highly accurate, FDA-cleared tools that assist pathologists in detecting, subtyping, and analyzing cancer across 40+ types using millions of digitized slides. Its flagship products—Paige Prostate Suite, Paige Breast Suite, Paige GI Suite, and Paige PanCancer Suite—leverage foundation models like Virchow and PRISM, enabling real-time insights and streamlined workflows. Paige Alba™, a proprietary multi-modal co-pilot, integrates voice and text commands to automate tasks such as stain ordering and report generation, enhancing efficiency and supporting precision medicine. With robust clinical validation, including 70% reduction in diagnostic error and up to 65.5% faster diagnosis times, Paige.ai stands at the forefront of AI in oncology. The platform seamlessly integrates with existing digital pathology systems and supports research and drug development with advanced biomarker discovery capabilities.

Key Features:

• Paige Prostate Suite: AI-powered detection and diagnosis of prostate cancer on H&E-stained whole-slide images, including Paige Prostate Detect (FDA-approved), Grade & Quantify, and Perineural Invasion (PNI).
• Paige Breast Suite: Tools for detecting breast cancer, mitoses, lymph node metastases, and HER2 status, with Paige Breast Lymph Node achieving 98% sensitivity.
• Paige GI Suite: AI for detecting and classifying benign and malignant conditions in gastrointestinal tissues, including colon carcinoma and MSI-H/dMMR phenotypes.
• Paige PanCancer Suite: First AI application to detect cancer across multiple tissues and organs, validated on 21 biopsy and 25 resection types with a specimen-level AUC of 0.95.
• Paige Alba™: A clinical-grade, multi-modal AI co-pilot that integrates pathology, radiology, and clinical data with agentic AI, voice, and text commands to automate workflows and support tumor board collaboration.
• OmniScreen™ Technology: AI-driven prescreening and characterization for simultaneous detection of over 1,600 biomarkers from H&E slides alone.
• Foundation Models: Advanced models like Virchow, Virchow2, Virchow2G, Virchow2G-Mini, and PRISM trained on 25 million slides and 350,000 patient cases.
• Regulatory Compliance: FDA-cleared, 13 CE-IVD Marks, 13 UKCA Marks, and certifications including ISO 13485, ISO 27001, HIPAA, GDPR, and GxP.
• Global Data Diversity: Trained on data from 800+ labs and institutions across 45+ countries, ensuring broad representation across gender, race, and geography.
• Seamless Integration: Compatible with major digital pathology platforms, enabling flexible deployment without vendor lock-in.
• Research & Development Support: Offers custom AI development, regulatory strategy, and commercialization support for pharmaceutical and life sciences partners.
• Clinical Validation: Backed by independent studies showing significant improvements in speed, accuracy, and diagnostic consistency.

Pricing: Paige.ai offers a 30-day free trial for its AI tools, making it accessible for evaluation and integration testing. This trial model aligns with its focus on clinical adoption and validation, providing a risk-free way for healthcare institutions to experience the platform’s capabilities.

Conclusion: Paige.ai is a transformative force in oncology, combining clinical-grade AI, deep data diversity, and regulatory excellence to empower pathologists and researchers with faster, more accurate cancer diagnostics and insights—setting a new standard in precision medicine and advancing the future of cancer care.